Nov 9 (Reuters) - Hologic on Thursday reported fourth-quarter sales that beat Wall Street estimates on strong demand in its breast health segment, sending the medtech firm's shares up 2.7% in extended trading.
The company now expects first-quarter adjusted per-share earnings between $0.92 and $0.97, compared with estimates of $0.94, according to LSEG data.
Hologic manufactures and supplies diagnostic tests, medical imaging systems and surgical products.
The company's breast health segment reported sales of $352.8 million in the fourth quarter, compared with estimates of $345.08 million.
Hologic posted revenue of $945.3 million that beat estimates of $940.04 million. (Reporting by Pratik Jain in Bengaluru; Editing by Shounak Dasgupta)
If you adored this post and you would like to obtain additional information pertaining to external wooden doors kindly go to our web site.
The company now expects first-quarter adjusted per-share earnings between $0.92 and $0.97, compared with estimates of $0.94, according to LSEG data.
Hologic manufactures and supplies diagnostic tests, medical imaging systems and surgical products.
The company's breast health segment reported sales of $352.8 million in the fourth quarter, compared with estimates of $345.08 million.
Hologic posted revenue of $945.3 million that beat estimates of $940.04 million. (Reporting by Pratik Jain in Bengaluru; Editing by Shounak Dasgupta)
If you adored this post and you would like to obtain additional information pertaining to external wooden doors kindly go to our web site.
